Antibiotic resistance lasts up to 12 months

May 20, 2010 11:07 am | Updated 11:07 am IST - London

Antibiotic medicines. File Photo: R. Ragu

Antibiotic medicines. File Photo: R. Ragu

Patients who take prescribed antibiotics in primary care can go on to develop a resistance lasting up to a year, according to a study.

It is known that resistance to antibiotics is a major threat to public health. However, researchers aid that this is not seen by most clinicians or patients as a reason to refrain from using them, with many regarding the problem as minimal.

To address a lack of systematic reviews in the area, the authors analysed 24 existing studies of resistance in individual patients prescribed antibiotics in primary care, mainly for respiratory or urinary infections. They found strong evidence that individuals prescribed an antibiotic in primary care for a respiratory or urinary infection develop a resistance.

The effect is greatest in the month immediately after treatment, but may last for up to a year, and this residual effect may be a driver for high levels of resistance in the community. The review provides the evidence needed to quantify the link between individual prescribing decisions and the problem of resistance, concluded the authors. They say it highlights that the only way to avoid the “vicious cycle of resistance” is to avoid the initial use of antibiotics wherever possible. However, they also call for more clinical trials to strengthen the evidence base.

In an accompanying analysis, two specialists in economics and health policy argue that new antibiotics to tackle multi-drug resistant bacteria are much needed. They show how financial incentives might be used to persuade drug companies to develop new antibiotics, and suggest that such action needs to be accompanied by efforts to tackle overuse of antibiotics, which is currently fuelling the spread of resistant bacteria.

Three international experts reiterated the above views in an editorial and called for economic strategies to bring new drugs to market, and to conserve existing antibacterials. “Nothing less than the future of medicine, from organ transplants to chemotherapy, is at stake, and there will be no second chances,” the British Medical Journal quoted them as concluding. The study has been published on bmj.com.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.